NCT06608199View on ClinicalTrials.gov

A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 Vaccine

PHASE3RecruitingINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

June 1, 2025

Study Completion Date

October 1, 2026

Conditions
Pneumococcal VaccinesPneumococcal Infections
Interventions
BIOLOGICAL

pneumococcal disease prevention

2P+1 programme of PCV13

Trial Locations (3)

40161

NOT_YET_RECRUITING

Universitas Padjadjaran Bandung, Bandung

80114

NOT_YET_RECRUITING

Faculty of Medicine Udayana University, Denpasar

Unknown

RECRUITING

Faculty of Medicine, padjadjaran University, Bandung

Sponsors
All Listed Sponsors
lead

Beijing Minhai Biotechnology Co., Ltd

INDUSTRY